Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
See tonight’s solar storm unfold across the world - 2Firefighters rescue two Israelis trapped in vehicles on flooded roads in West Bank
- 3ByHeart infant formula recall tied to botulism outbreak puts parents on edge
- 4Vote in favor of Your Fantasy Vehicle: Which Notable Model Catches Your Heart?
- 5Storm Goretti sweeps United Kingdom, France with winds over 120 mph
- Ukraine demands army of 800,000 under peace plan
- 'A prank': Israel Police detain suspect for shooting rubber bullets at Ashkelon kindergarten
- Why home maintenance deserves a spot in the annual health and budget plans
- Make your choice for the sweet that transports you to its nation of beginning!
- Nestlé recalls infant formula in 49 countries. See list.
- I visited the largest collection of public telescopes in the US in Oregon's high desert, and the dark skies blew me away
- As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
- When Would it be a good idea for you to Look for Help from a Criminal Legal counselor?
- Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
